Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis announced that eleven clinical sites are now open for enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib. The company reaffirmed guidance for the dosing of the initial five patients by the end of July 2026, with data expected in December 2026.
Key figures
- Target dosing date
- end of July 2026
- Target data readout
- December 2026
- Active clinical sites
- 11
- Reverse split ratio range
- 1-for-5 to 1-for-25
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.